US Patent 7,435,427: Isotretinoin Lipid-Capsule Claims, Scope, Expiration and Patent Landscape

US Patent 7,435,427 covers oral isotretinoin capsules containing a semi-solid, lipid-based suspension designed to improve delivery of isotretinoin. The independent composition claim requires four core elements: isotretinoin, a capsule, a hydrophilic lipidic excipient with an HLB of at least 10, an oily vehicle, and an additional surfactant. The patent also claims dosage strength, excipient selection, capsule type, emulsions, manufacturing processes and daily administration.

The patent is most relevant to lipid-based isotretinoin products such as Absorica and related formulations. Its broad composition claim is materially narrower than a claim to isotretinoin generally because it requires a specific multi-component lipid system and numerical concentration ranges. The patent’s original United States term has expired under the ordinary 20-year patent-term calculation, subject to any patent-term adjustment or extension reflected in the official USPTO record.[1]

What does US Patent 7,435,427 protect?

The patent protects a pharmaceutical formulation rather than isotretinoin as an active pharmaceutical ingredient. Claim 1 requires the following combination:

Required element	Claim requirement
Active ingredient	Isotretinoin
Dosage form	Pharmaceutically acceptable capsule
Physical form	Semi-solid suspension
Hydrophilic lipid	20% to 80%; HLB at least 10
Hydrophilic lipid classes	Glyceroyl macrogolglycerides, polyethylene glycol esters or mixtures
Oily vehicle	5% to 70%
Oily vehicle classes	Vegetable oils, medium-chain triglycerides, fatty-acid esters, glycerol oleate or mixtures
Additional surfactant	1% to 10%
Administration route	Oral, for the composition claims

The claim uses the term “comprises.” That language ordinarily permits additional excipients or formulation components unless another claim limitation is avoided. A competing formulation could therefore contain ingredients beyond those recited in claim 1 and still fall within the claim if every required element remains present.

How does the HLB limitation affect claim scope?

The hydrophilic lipid must have an HLB value of at least 10 under claim 1. Claims 2 and 3 narrow the threshold to at least 12 and at least 13, respectively.

HLB, or hydrophilic-lipophilic balance, is a formulation parameter used to classify surfactants and emulsifying agents. The claim does not cover every hydrophilic excipient. It limits the qualifying component to:

Glyceroyl macrogolglycerides;
Polyethylene glycol esters; or
Mixtures of those materials.

Claims 17 and 15 narrow the formulation further. Claim 17 identifies glycerol macrogolglycerides, while claim 15 requires an additional excipient with an HLB of at least 12 and soybean oil as the oily vehicle.

The exact identity, grade, nomenclature and measured HLB of an excipient would be important in an infringement analysis. Commercial excipients can be sold under trade names and may contain mixtures of glycerides and polyethylene glycol derivatives. The patent specification and technical evidence would determine whether a particular commercial grade satisfies the claimed category and HLB threshold.

How many patents cover the core isotretinoin formulation?

The relevant intellectual-property estate is broader than US 7,435,427. It can be divided into four groups:

The original lipid-composition patent represented by US 7,435,427.
Later patents directed to specific lipid systems, low-food-effect delivery or improved isotretinoin absorption.
Formulation and manufacturing patents covering capsule filling, melting and homogenization.
Method-of-use patents covering acne treatment, dosing and administration schedules.

The commercial product landscape includes conventional isotretinoin softgels and newer lipid-based products. Absorica is the principal commercial example associated with a lipid-based isotretinoin delivery approach. Conventional products have included Accutane, Claravis, Amnesteem, Sotret, Myorisan and Zenatane. These products do not necessarily use the formulation architecture claimed in US 7,435,427.

A patent-number count alone is not an adequate freedom-to-operate measure. The relevant questions are whether a patent is unexpired, listed for the specific product, claim-covering for the proposed formulation, and enforceable against the proposed manufacturing and marketing activities.

What formulations are protected by US 7,435,427?

Hydrophilic lipidic excipients

The central hydrophilic-lipid requirement covers glyceroyl macrogolglycerides and polyethylene glycol esters. In commercial formulation practice, this language may reach lipid excipients that combine glycerides with polyethylene glycol components and provide self-emulsifying or dispersion-enhancing properties.

Claims 1, 12, 15 and 17 create the principal formulation coverage:

Claim	Added limitation
1	Hydrophilic lipid at 20% to 80%, oily vehicle at 5% to 70%, surfactant at 1% to 10%
2	Hydrophilic lipid HLB of at least 12
3	Hydrophilic lipid HLB of at least 13
12	Express weight percentages and glyceroyl macrogolglycerides
15	HLB of at least 12 and soybean oil
17	Glycerol macrogolglycerides
18	Medium-chain triglyceride oily vehicle

Claim 12 is particularly important because it expressly recites weight percentages. It reduces potential ambiguity over the concentration basis, although the claim language still requires analysis of whether each percentage is measured against the total composition, the fill mass or another formulation basis.

Oily vehicles

The oily vehicle can be a single material or a mixture. The listed classes include vegetable oils, medium-chain triglycerides, fatty-acid esters and glycerol oleate.

Claim 18 specifically identifies medium-chain triglycerides. Claim 15 identifies soybean oil. A formulation using another vegetable oil may still fall within claim 1 if the remaining requirements are met.

Additional surfactants

Claim 4 provides a broad list of secondary surfactants, including:

Sorbitan fatty-acid esters;
Polysorbates;
Polyoxyethylene sorbitan fatty-acid esters;
Sodium lauryl sulfate;
Lecithin;
Propylene glycol esters;
Glycerol fatty-acid esters; and
Polyethylene glycol.

The secondary surfactant must be present in the amount required by claim 1, generally 1% to 10%. A formulation with no separate additional surfactant would face a substantial noninfringement argument, unless another component is shown to satisfy that claim element.

Disintegrants and capsules

Claims 5 and 6 add disintegrants, specifically povidone and sodium croscarmellose. Claims 7 covers hard gelatin, soft gelatin, hypromellose and starch capsules.

The capsule limitation matters because a liquid or semi-solid isotretinoin formulation delivered in a bottle, tablet, powder sachet or non-capsule dosage form would not literally satisfy the capsule limitation. A softgel product is the most obvious dosage form within the claim.

Dose limitations

Claims 8 and 9 cover compositions containing approximately 10 mg to 20 mg and 16 mg to 20 mg of isotretinoin, respectively. Claims 10 and 11 cover administration of approximately 10 mg to 20 mg as a total daily dose, with claim 11 narrowing the range to 16 mg to 20 mg.

These claims do not cover all isotretinoin dosing. They focus on a low-dose range that may correspond to particular commercial product strengths or dosing regimens.

Does US 7,435,427 cover isotretinoin emulsions?

Yes. Claim 16 states that the isotretinoin is contained within an emulsion. This claim narrows claim 1 but may be commercially important because lipid formulations can form emulsions or self-emulsifying dispersions after contact with gastrointestinal fluids.

The claim set distinguishes between:

The semi-solid suspension required by claim 1;
An emulsion under claim 16; and
A composition filled after mixing or pre-melting under claims 13 and 14.

Whether a product is a “semi-solid suspension” or an “emulsion” would likely depend on formulation characterization, microscopy, rheology, phase behavior, manufacturing records and the patent specification’s definitions. A product labeled as a lipid solution could still be assessed according to its actual physical state rather than its marketing description.

What manufacturing processes are protected?

Claims 13 and 14 add capsule-filling process limitations. They cover capsule filling after mixing isotretinoin with one or more lipidic excipients, including pre-melted excipients.

Claim 13 requires a process involving:

Isotretinoin;
One or more pre-melted lipidic excipients; and
Filling the resulting composition into a capsule.

Claim 14 recites mixing:

Isotretinoin;
One or more hydrophilic lipidic excipients;
The oily vehicle; and
Disintegrants, surfactants or combinations of those ingredients.

These claims may create evidentiary issues because they appear as composition claims containing process language. In an enforcement dispute, the patentee would need to establish both the claimed product characteristics and the relevance of the manufacturing steps. Manufacturing records, batch instructions and process validation documents would be central to the analysis.

The patent does not claim every method of producing an isotretinoin capsule. A manufacturer using a dry-fill process, a different sequence of addition or a formulation that does not use pre-melted excipients may have a design-around position, provided the resulting product does not independently satisfy the composition claims.

When does US 7,435,427 lose exclusivity?

The patent’s original term is governed by the United States patent term applicable to its earliest effective nonprovisional filing date, rather than by the 2008 issue date.[1] The patent is no longer a live barrier under the ordinary term calculation. Any remaining relevance is historical, evidentiary or relevant to past sales, not an ordinary forward-looking exclusivity right.

Patent-term adjustment, patent-term extension, terminal disclaimers and post-grant status must be checked in the USPTO Patent Center record. The FDA Orange Book separately identifies listed patents and regulatory exclusivity. Orange Book listing does not extend the patent term and does not itself establish that every claim covers every product.[2]

What was the Orange Book status?

The patent was associated with the lipid-based isotretinoin product franchise, particularly Absorica-related patent protection. Orange Book analysis should distinguish:

Whether US 7,435,427 was listed for a particular NDA;
Whether the listing was active or expired;
Whether the listed patent covered the drug substance, formulation or method of use;
Whether the NDA holder had submitted a timely patent-status update; and
Whether a listed patent remained enforceable on the proposed launch date.

A historical Orange Book listing would not by itself establish current exclusivity. The FDA Orange Book identifies patents submitted by NDA holders, while the USPTO controls the patent register and legal term.[2]

Which companies challenged isotretinoin patent protection?

The competitive field has included generic manufacturers of conventional isotretinoin capsules and companies developing lipid-based alternatives. The principal commercial distinction is between:

Product category	Formulation profile	Patent exposure
Conventional isotretinoin softgels	Isotretinoin in an oil-based capsule	Primarily product, formulation and method patents applicable to the specific product
Lipid-based isotretinoin	Semi-solid or self-emulsifying lipid suspension	Higher risk under claims requiring hydrophilic lipid, oily vehicle and surfactant
Alternative delivery systems	Modified excipient system or different capsule process	Potential design-around, subject to full claim mapping
Generic conventional capsules	Typically approved through ANDA pathway	Paragraph IV exposure depends on the patents listed for the referenced NDA

A Paragraph IV certification is product- and NDA-specific. The claims supplied do not establish that any particular manufacturer filed a Paragraph IV certification, that litigation was commenced, or that a settlement was reached. Those conclusions require the FDA Orange Book, ANDA litigation records and court docket review.

What generic entry risks exist?

Conventional isotretinoin generics

A generic conventional isotretinoin capsule may avoid US 7,435,427 if it lacks the required hydrophilic lipidic excipient, falls outside the claimed concentration ranges, or does not contain the claimed combination of oily vehicle and additional surfactant.

The patent therefore presents limited risk to products using a materially different oil system or a conventional formulation that does not meet the HLB requirement.

Lipid-based generics

A lipid-based generic presents greater risk if it uses:

A glyceroyl macrogolglyceride or polyethylene glycol ester;
A vegetable oil or medium-chain triglyceride;
A separate surfactant;
The claimed concentration ranges; and
A capsule containing a semi-solid suspension.

A formulation can avoid literal infringement by changing one required element, but the doctrine of equivalents could remain relevant if the substituted component performs substantially the same function in substantially the same way with substantially the same result.

Biosimilar risk

Biosimilar risk is not applicable. Isotretinoin is a small-molecule retinoid, not a biologic. Market entry proceeds through the ANDA or other small-molecule pathway rather than the abbreviated biosimilar pathway under the Public Health Service Act.

How strong is the patent estate?

The patent had meaningful historical strength against a formulation that closely reproduced the claimed lipid architecture. Its strongest features were:

A defined combination of hydrophilic lipid, oily vehicle and surfactant;
Numerical concentration ranges;
Specific excipient classes;
Coverage of capsules and emulsion embodiments;
Low-dose isotretinoin claims; and
Manufacturing-process limitations.

Its principal weaknesses were claim specificity and design-around potential. A competitor could investigate:

A non-capsule dosage form;
A hydrophilic component outside the claimed chemical categories;
An HLB below 10;
A formulation outside the concentration ranges;
A non-lipid delivery system;
A different surfactant architecture; or
A manufacturing process that avoids the claimed filling steps.

Because the patent term has expired under the ordinary calculation, these strengths no longer create prospective market exclusivity. They remain relevant to historical infringement, validity analysis and interpretation of later patent filings.

What patent litigation and settlements affect the patent?

The claim text alone does not establish a current infringement action, Paragraph IV case or settlement involving US 7,435,427. Any litigation assessment must separate:

Cases involving conventional isotretinoin products;
Cases involving Absorica or other lipid-based products;
Challenges to US 7,435,427 itself;
Challenges to later patents in the same product franchise; and
Regulatory litigation concerning FDA approval or patent listing.

A settlement concerning a later patent would not necessarily resolve the enforceability of US 7,435,427. Likewise, a court decision involving a different isotretinoin formulation would not automatically determine infringement of these claims.

Key Takeaways

US 7,435,427 claims a lipid-based oral isotretinoin capsule, not isotretinoin generally.
Claim 1 requires a hydrophilic lipid with HLB of at least 10, an oily vehicle, an additional surfactant and a semi-solid suspension.
Claims 2 through 18 narrow the scope by HLB, excipient identity, oil type, dose, capsule type, emulsion status and manufacturing process.
Medium-chain triglycerides, soybean oil, glyceroyl macrogolglycerides, disintegrants and softgel capsules are expressly addressed in dependent claims.
Conventional isotretinoin generics may avoid the patent if they do not use the claimed multi-component lipid system.
Biosimilar competition is irrelevant because isotretinoin is a small molecule.
The patent’s original United States term has expired under the ordinary patent-term framework.
Current commercial risk depends principally on later patents, Orange Book status for the relevant NDA and the exact formulation used by the proposed product.
The claims support design-around strategies based on excipient identity, HLB, concentration, dosage form and manufacturing sequence.

FAQs About US Patent 7,435,427

Does US 7,435,427 cover Accutane?

It does not cover isotretinoin as a drug substance. Accutane would fall within the patent only if its formulation satisfied all relevant claim limitations, including the specified hydrophilic lipid, oily vehicle, surfactant, concentration ranges and capsule form.

Does the patent cover Absorica?

The patent is associated with the lipid-based isotretinoin product franchise that includes Absorica-related intellectual property. Product coverage must be determined by comparing the approved formulation with each claim and by reviewing the applicable Orange Book listing.

Can a generic use medium-chain triglycerides?

Yes, but medium-chain triglycerides create a potential limitation under claim 18 and may also satisfy the oily-vehicle element of claim 1. The generic would need to assess every remaining claim element.

Is a softgel automatically infringing?

No. A softgel satisfies only the capsule-format aspect of claim 7. Infringement also requires the claimed isotretinoin suspension, hydrophilic lipid, oily vehicle, surfactant and concentration ranges.

Can a formulation avoid the patent by changing the surfactant?

Potentially. The formulation would still need to avoid the broad additional-surfactant limitation in claim 1, not merely the narrower list in claim 4. A different surfactant may remain within the scope of claim 1 depending on its identity, function and concentration.

References

United States Patent and Trademark Office. (2008). US Patent No. 7,435,427, pharmaceutical compositions containing isotretinoin.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
U.S. Food and Drug Administration. (2012). Absorica isotretinoin capsules: Prescribing information.
United States Code. (2023). 35 U.S.C. §§ 154, 156 and 271.

PCT Information
PCT Filed	September 21, 2001	PCT Application Number:	PCT/BE01/00163
PCT Publication Date:	March 28, 2002	PCT Publication Number:	WO02/24172

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	270544	⤷ Start Trial
Australia	8943801	⤷ Start Trial
Brazil	102013032172	⤷ Start Trial
Canada	2423170	⤷ Start Trial
Canada	2836228	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,435,427

Summary for Patent: 7,435,427